-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $55

Benzinga·09/18/2026 13:27:54
Listen to the news
Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $71 to $55.